Parnate

Quick links to important sections

Parnate

Treatment option: Clinical Depression

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parnate

Property Description
Active ingredient Tranylcypromine sulfate
Form Film-coated tablets
Pharmacological class Monoamine Oxidase Inhibitor (MAOI)
Common use Modulating mood and emotional well-being
Origin Synthetic psychotropic agent

Parnate: An Antidepressant Classified as an MAOI

Parnate is a potent, prescription-only psychotropic agent belonging to the Monoamine Oxidase Inhibitor (MAOI) class of Antidepressants. Its active pharmaceutical ingredient is Tranylcypromine sulfate, which is a synthetic compound structurally related to substituted phenethylamines. This class of drug is clinically recognized for its potent effects in managing mood disorders.

Tranylcypromine is categorized within the pharmacologic class of MAOIs. Parnate is specifically characterized as an irreversible, non-selective inhibitor, a distinguishing feature that highlights its broad and sustained enzymatic action. It is supplied for oral administration in the form of film-coated tablets.

Composition and General Therapeutic Purpose

Parnate is formulated as a single active ingredient product, consisting of Tranylcypromine sulfate along with standard solid excipients used in tablet production. It is not a combination drug.

The general purpose of this medication stems from its function to modulate key brain chemicals. By inhibiting the action of the Monoamine Oxidase (MAO) enzymes—which normally break down neurotransmitters—the drug preserves and increases the available concentration of mood-regulating monoamines, such as Serotonin, Norepinephrine, and Dopamine. This mechanism is the basis for its specialized application; the resulting sustained increase in chemical signaling helps to rebalance neurochemistry and alleviate symptoms associated with severe, chronic mood disturbances.

What side effects are possible with Parnate?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Tranylcypromine sulfate (Parnate) primarily based on its effects across several System-Organ Classes, most notably the Vascular and Nervous Systems. Adverse reactions are categorized by frequency to reflect their reported occurrence.

Commonly documented adverse effects include orthostatic hypotension (a drop in blood pressure upon standing), insomnia, dizziness, dry mouth, and constipation. These effects are often more noticeable during the initial phases of treatment. Other reported effects fall into Uncommon or Rare categories, which may involve tachycardia, palpitations, or tremors.

Serious Adverse Reactions and Safety Constraints

The safety profile is defined by the risk of several Serious Adverse Reactions. The most critical is Hypertensive Crisis, a severe elevation in blood pressure often triggered by the ingestion of tyramine-rich foods or specific medications. Regulatory constraints mandate a strict dietary restriction throughout treatment and for two weeks after discontinuation due to the drug's irreversible action. Another rare but serious concern is Serotonin Syndrome, which requires vigilance, particularly if the medicine is co-administered with other serotonergic agents.

Population-Specific Safety Notes include warnings regarding a potentially increased risk of suicidal thoughts and behaviors in younger patients (under 25) during initial therapy or dose changes. Additionally, older adults may exhibit greater sensitivity to the hypotensive effects, which is a key factor noted for cautious use in this population.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Tranylcypromine sulfate, the active ingredient in Parnate, is a documented medical emergency. According to regulatory labeling, any suspected overdosage requires the individual to seek immediate medical attention and necessitates hospitalization.

Documented Manifestations and Critical Outcomes

Symptoms may be significantly delayed, with severe manifestations appearing up to 12 hours post-ingestion and peaking within 24 to 48 hours. Initial signs documented in regulatory information include restlessness, dizziness, agitation, and a feeling of impending death. These may progress to life-threatening complications.

System Affected Documented Severe Manifestations
Neurological Convulsions, coma, hyperreflexia, opisthotonos
Cardiovascular Hypertensive crisis, circulatory collapse, cardiac arrhythmias

Official Emergency Response

The most serious outcomes documented in official sources include intracranial bleeding due to severe hypertension and death. Due to the delayed and potentially fatal nature of the toxicity, continuous observation and monitoring are required for a minimum of 48 hours.

There is no specific antidote known for Tranylcypromine overdose. Management is officially described as symptomatic and supportive, including procedures like gastric lavage, activated charcoal, and the use of rapidly-acting alpha-adrenergic blocking agents for severe hypertension, as warranted and documented in regulatory prescribing information.

Therapeutic Uses of Parnate

What Parnate Treats: Main Uses and Benefits

Parnate is primarily used to address the profound and persistent symptoms of Major Depressive Disorder when the condition has been classified as Treatment-Resistant Depression (TRD). This medication is commonly used when other types of antidepressant medications have not provided sufficient relief. It may provide supportive management for the heavy burden of a prolonged, severe low mood.

The therapeutic focus is on easing symptom clusters that include low mood, loss of energy (anergy), and an inability to feel pleasure (anhedonia). It is also relevant for managing the distinct symptom pattern of Atypical Depression, which may involve changes in sleeping, heightened appetite, and specific physical manifestations. By helping to manage these difficult symptoms, the medication provides supportive relief when symptoms interfere with routine activities, and assists with functional stability.


Quick Fact: Use in Challenging Symptoms Parnate is commonly used across conditions presenting with acute episodes and significant symptomatic burden.

Eligibility and Restrictions for Use

Eligibility for Parnate Use

Parnate (tranylcypromine) is officially approved for use in adult patients with Major Depressive Disorder who have not responded adequately to other antidepressants. The safety and efficacy of Parnate have not been established in the pediatric population and it is not approved for use in children or adolescents (under 18 years) [1.5, 2.2]. Use in older adults requires great caution and careful monitoring [1.5, 2.1].

Contraindicated Populations

The medicine is strictly contraindicated in several patient groups, primarily due to the risk of hypertensive crisis or severe reactions. Prohibited populations include those with cerebrovascular defects or established cardiovascular disease, severe hypertension, or pheochromocytoma [1.2, 2.4]. Patients with a history of liver disease or impaired hepatic function are also excluded [2.7].

Use is prohibited if the patient is currently taking or has recently discontinued other MAO inhibitors, SSRIs, SNRIs, tricyclic antidepressants, or sympathomimetic agents, requiring a mandatory medication-free interval [1.2, 2.2]. Parnate is not recommended for pregnant or breastfeeding patients as safety in these populations is not established [1.3, 2.5].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Parnate's (Tranylcypromine) interaction profile is defined by mandatory contraindications established in regulatory labeling, primarily due to its classification as an irreversible, non-selective Monoamine Oxidase Inhibitor (MAOI). The major interaction mechanisms involve pharmacodynamic potentiation that can lead to excessive levels of monoamines, resulting in severe outcomes such as Hypertensive Crisis or Serotonin Syndrome.


Official Interaction Restrictions

Classification Key Restrictions
Contraindicated Combinations Prohibited co-administration with other MAOIs (including Linezolid), SSRIs, SNRIs, certain Opioid Analgesics (e.g., Meperidine, Tapentadol), Sympathomimetic agents, and Dextromethorphan.
Dietary and Substance Mandatory avoidance of Tyramine-rich foods and beverages (e.g., aged cheeses, cured meats) and Alcohol. Excessive caffeine consumption should also be avoided.
Timing Requirements Mandatory washout periods are required when switching between Parnate and contraindicated agents. For instance, at least five weeks must pass after discontinuing Fluoxetine before initiating Parnate.

Pharmacokinetic and Population Notes

The interaction profile includes pharmacokinetic inhibition of the CYP2C19 and CYP2A6 liver enzymes. Additionally, the drug is officially contraindicated in patients with impaired hepatic function due to specific handling restrictions noted in the regulatory documents. These restrictions govern the use and administration sequencing of Tranylcypromine.

Mechanism of Action

Parnate (tranylcypromine) exerts its action through multiple distinct biochemical domains, primarily modulating key regulatory pathways in the central nervous system.

The core mechanism involves acting as a nonselective and irreversible inhibitor of monoamine oxidase (MAO) enzymes, specifically MAO-A and MAO-B. This interaction blocks the primary metabolic breakdown of key monoamine neurotransmitters, including serotonin, norepinephrine, and dopamine. The resulting accumulation leads to a substantial increase in monoamine availability at the synaptic cleft, thereby altering signaling characteristics within targeted neural pathways.

Additionally, at higher concentrations, tranylcypromine engages a secondary mechanistic domain by functioning as a weak norepinephrine reuptake inhibitor. This modulates the process by which norepinephrine is cleared from the synapse, increasing its synaptic residence time and leading to enhanced engagement of postsynaptic receptors.

A third, distinct mechanistic cascade involves the inhibition of lysine-specific demethylase 1 (LSD1), a histone demethylase enzyme. This enzyme-mediated signaling affects systems regulating gene transcription, influencing the transcriptional regulation of specific target genes within cellular systems.

Dosage and Administration Information

The administration of tranylcypromine sulfate (Parnate) is managed through a structured dosing protocol. The medication is supplied as a 10 mg film-coated tablet and is intended for oral administration.

Standard Dosing and Schedule

The treatment typically begins with an initial total daily dosage of 20 mg, usually administered in divided doses. The dosage may subsequently be increased in increments of 10 mg per day at intervals of one to three weeks. The usual effective daily dosage for ongoing maintenance is often between 30 mg and 40 mg. The maximum recommended daily intake is 60 mg.

The tablets are generally taken in the morning and afternoon. Standard guidance specifies that the last dose of the day should be taken no later than 3:00 PM to mitigate the potential for sleep interference. Administration is independent of specific meal timing.

Procedural Use and Adjustments

Parnate is used as part of a long-term plan. If an adequate response is not achieved, an evaluation is conducted after four weeks at the maximum recommended dose. Standard guidelines describe use for specific populations; specifically, older adults require a lower initial dose and a more gradual titration schedule.

When discontinuing the medication, the protocol dictates that the dose must be reduced slowly and gradually (tapering) to complete the course of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Parnate (Tranylcypromine)

Evidence for Use in Major Depressive Disorder (MDD)

Parnate was evaluated in research concerning adults with Major Depressive Disorder, particularly in research exploring how symptoms change over time. The evidence base includes short-term Randomized Controlled Trials (RCTs) and historical studies that research examined the measured changes compared to non-active substances (placebo) or older classes of antidepressants. These trials monitored outcomes related to symptom intensity or variability, often using standardized rating scales to measure depressive symptom change.

Findings describe patterns observed in the studies over acute, defined time intervals, typically spanning four to six weeks. Research highlights changes measured in symptom scores, where patterns of difference were observed in some studies when compared to placebo. The evidence is largely historical, which limits direct comparison with contemporary reference treatments.

Evidence for Use in Treatment-Resistant Depression (TRD)

These studies often involved small populations of adults who had failed to respond to a minimum number of prior antidepressant medications. The research explored measurement of changes in symptom scores in these specialized cohorts. Systematic reviews of this evidence explore the compound's place in the broader evidence landscape for conditions characterized by chronic, disruptive episodes. Despite these findings, the definitions of TRD were observed in some studies to be highly heterogeneous, meaning the results apply only to the populations studied under those specific definitions.

Focus on Atypical Depression and Special Populations

Research examined the measurement of symptom changes in a specific subgroup of MDD known as Atypical Depression. Older comparative research describes patterns of measured change in these atypical features observed during the studies. However, the majority of evidence for Atypical Depression is limited and derived from research conducted decades ago.

Research in Special Populations is generally limited. Subgroup findings are uncertain or limited for certain populations, such as children, adolescents, or women who are pregnant or breastfeeding. In highly specialized research contexts, Parnate was evaluated in small, exploratory studies involving adults with Bipolar Disorder who were experiencing a depressive phase.

Gaps and Limitations in the Research Landscape

Long-term effects are not fully established, and there is limited information for long-term outcomes that reflect functional measures or symptom stability over a period of many months or years. Comparative evidence is lacking for a direct assessment against many other contemporary antidepressant compounds. The available research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Tranylcypromine - StatPearls (Source for FDA indications, general context, and off-label uses)

Frequently Asked Questions (FAQ)

Common questions about Parnate (FAQ)


Q: What is the general duration someone might expect to take Parnate?

Official documents describe the use of Parnate as part of a long-term plan for managing depressive symptoms. The length of therapy is a decision made by the prescribing healthcare provider.


Q: Are there common patient reports of feeling tired or fatigued on Parnate?

Official prescribing information lists both fatigue and lethargy as reported adverse reactions that are documented in the safety profile of the medicine.


Q: Does Parnate have any effect on sleep patterns, like insomnia or drowsiness?

Official documents indicate that common documented effects include both insomnia and drowsiness. To reduce the chance of the medicine interfering with sleep, instructions specify that the last daily dose should generally be taken no later than 3:00 PM.


Q: Is Parnate known to cause weight gain or weight loss?

Official documents list a loss of appetite as a commonly reported side effect. Unusual weight gain is also documented as a serious, unlikely event in the safety profile.


Q: What is meant by the 'washout period' when switching to or from Parnate?

Washout periods are specific medication-free time intervals that are mandated when a patient is switching between Parnate and other contraindicated medicines. This time is required to allow the prior drug to clear the body completely, thereby reducing the risk of severe reactions when initiating Parnate.


Q: How soon after stopping Parnate can I start other medicines?

Due to the drug's sustained action, the MAO enzyme inhibition may persist for up to 10 days after the last dose. Official protocol states that a time period of at least one full week should elapse after discontinuing Parnate before starting another MAOI or a contraindicated antidepressant.


Q: Why is Parnate sometimes described as a 'last resort' medication?

The indication for Parnate's use is clearly defined in official regulatory documents. It is approved for adult patients with Major Depressive Disorder who have not responded adequately to other antidepressant treatments. This means it is generally used later in the treatment sequence, not for the initial management of depression.


Q: Are there any special considerations for older adults taking Parnate?

Official guidelines for older adults indicate that a lower initial dose and a more gradual titration schedule is described in official documents. This population may also exhibit a greater sensitivity to the hypotensive effects (low blood pressure) of the medication.


Q: Can Parnate be used by people who have other mental health conditions besides depression?

Parnate is approved only for the treatment of Major Depressive Disorder in adults. Furthermore, before treatment begins, official guidance suggests patients are screened for a history of mania or bipolar disorder due to the known risk of activating these conditions.


Q: Is it difficult to stop taking Parnate once treatment has started?

The official protocol for stopping Parnate indicates that the dose is typically reduced slowly and gradually (a process called tapering). This gradual reduction is necessary because withdrawal effects, including confusion or delirium, have been reported with abrupt discontinuation of the medicine.


Q: Are there any non-prescription supplements or vitamins that should be avoided with Parnate?

Official prescribing information states that over-the-counter medications, herbal products, or dietary supplements should be avoided without prior discussion with a healthcare provider. The supplement SAM-e (S-adenosyl-L-methionine) is specifically listed as a contraindicated product.


Q: Why are people often tested before they can start taking Parnate?

As a necessary precaution before starting treatment, official guidance recommends two primary checks. This includes screening patients for a history of mania and measuring blood pressure to establish a baseline for potential risks.


Q: What are the long-term expectations for people who use Parnate?

The available research evidence indicates that long-term effects are not fully established. There is limited information available regarding outcomes that reflect functional measures or symptom stability over many months or years of use.


Q: Can Parnate affect a person's energy levels?

Official documents list fatigue and lethargy as reported adverse effects. Conversely, very increased energy is a documented symptom that may be associated with the activation of a manic episode.


Q: What patient populations have been included in the main clinical research for Parnate?

Main clinical research has involved adult patients with Major Depressive Disorder (MDD), including those identified as having Treatment-Resistant Depression (TRD) and a subgroup known as Atypical Depression. Research exploring other populations is generally limited.


Q: Is Parnate usually taken once or multiple times a day?

Parnate is typically administered in divided doses, generally taken in the morning and mid-afternoon. The official instructions specify that the last dose of the day should be taken no later than 3:00 PM to help prevent sleep interference.


Q: Are there any specific lifestyle changes often associated with taking Parnate?

The use of Parnate requires strict adherence to mandatory lifestyle restrictions described in the product label. This includes absolute dietary restrictions (avoidance of Tyramine-rich foods) and avoidance of alcohol. Excessive caffeine consumption should also be avoided due to potential risks.


Q: What organs in the body are primarily affected by Parnate?

The drug's safety profile is classified based on its documented effects across the Vascular and Nervous Systems. Furthermore, Parnate is officially contraindicated (prohibited) in patients with impaired hepatic (liver) function due to how the drug is processed by the body.


Q: Can Parnate lead to problems with concentration or memory?

Official reports of combining Parnate with tryptophan have been associated with reported behavioral and neurologic syndromes. These syndromes include symptoms such as disorientation, confusion, and amnesia, which suggests a potential for cognitive effects.


Q: Is it common for people to switch from other antidepressants to Parnate?

Official prescribing information and the drug's indication address the scenario of switching, as Parnate is often used after a patient has had an inadequate response to other antidepressants. Mandatory washout periods are officially required when changing from other antidepressants to Parnate.


Q: What are some key pieces of information from the Parnate patient information leaflet?

Key information includes that the medicine is reserved for adults who have not responded well to other antidepressants. The leaflet also describes the requirement for close monitoring for suicidal thoughts and behaviors, and the critical risk of a dangerous increase in blood pressure if certain foods are not avoided.


Q: Are there known interactions between Parnate and nicotine or caffeine?

Official documents specify that excessive caffeine consumption should be avoided due to the potential for a dangerous increase in blood pressure. Nicotine is not explicitly listed as a contraindicated agent in the available official warnings.


Q: How does Parnate affect the body's neurotransmitter levels generally?

Parnate acts as an inhibitor of the MAO enzymes, which typically break down neurotransmitters. By blocking this process, the medicine increases the available concentration of key mood-regulating chemicals, including serotonin, norepinephrine, and dopamine.


Q: Are there different brand names for the drug Tranylcypromine?

The active pharmaceutical ingredient, Tranylcypromine sulfate, is available under the brand name Parnate. While this is the most common name, other brand names may exist or may have been used historically for the same active ingredient.


Q: What are the signs of a potential interaction that patients should know about?

Symptoms of a Hypertensive Crisis (a serious blood pressure elevation) can include a sudden, severe headache, neck stiffness, and fast or pounding heartbeats. Symptoms of Serotonin Syndrome can include agitation, confusion, sweating, shivering, or muscle stiffness.


Q: Does the time of day Parnate is taken matter?

Yes, the time of day for administration is considered important. Official instructions specify that the last dose of the day should be taken no later than 3:00 PM to help reduce the potential for sleep interference.


Q: Can Parnate affect appetite?

Yes, the safety information for Parnate lists loss of appetite as one of the commonly documented side effects of the medicine.


Q: Is it possible for Parnate to interact with herbal remedies?

Official prescribing information states that herbal products or dietary supplements should be avoided without prior discussion with a healthcare provider. Many of these products are contraindicated due to the risk of severe drug reactions, especially those that can affect serotonin levels.

How should Parnate be stored and disposed of?

Storage Requirements

Official regulatory documents require Parnate (tranylcypromine) tablets to be stored at Controlled Room Temperature, which is generally defined as 20 C to 25 C (68 F to 77 F), with allowance for temperature variations up to 30 C (86 F). The medicine must be kept from freezing and stored away from excess heat, moisture, and direct light.

To ensure stability and safety, the tablets must remain in their tightly closed, light-resistant container and be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Parnate should be disposed of using a drug take-back program whenever possible. If a take-back option is unavailable, the tablets may be mixed with an undesirable substance (such as used coffee grounds), placed in a sealed container to prevent leakage, and then discarded in the household trash. The medication must not be used after its labeled expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Parnate found in:

A-Z Index: